Follow-up of cystic pineal glands in retinoblastoma patients does not increase detection of pineal trilateral retinoblastoma.

MRI Pediatric Retinoblastoma Trilateral retinoblastoma Trilateral retinoblastoma incidence imaging oncology pineal cyst pineal gland pineoblastoma radiology screening

Journal

American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500

Informations de publication

Date de publication:
09 Jul 2024
Historique:
received: 08 01 2024
revised: 14 06 2024
accepted: 02 07 2024
medline: 12 7 2024
pubmed: 12 7 2024
entrez: 11 7 2024
Statut: aheadofprint

Résumé

To evaluate the effectiveness of baseline screening and follow-up with MRI to detecting trilateral retinoblastoma (TRb) and assessing the risk of TRb development. Prospective multicenter cohort study METHODS: A total of 607 retinoblastoma patients from 2012 through 2022 were included and followed up until 1-9-2023. At each center a neuroradiologist categorized pineal glands on baseline and follow-up scans into four groups: (A) normal, (B) cystic gland, (C) suspicious gland, or (D) TRb. Different follow-up schedules were assigned to each category. Categories (B) and (C) were followed-up with MRI after approximately 3-months and after another 3 months if suspicion remained. On each MRI, they measured the height and width, evaluated the aspect (solid, partly cystic and completely cystic) of the pineal gland and evaluated radiological features suspicious of pineal TRb. The effectiveness of the current TRb screening method was assessed by evaluating its sensitivity and specificity to detect TRb. Determining the TRb incidence was a secondary outcome measure. Heritable retinoblastoma patients had a risk of 3.78% to develop TRb. One out of four pineal TRbs was detected during a follow-up scan and four out of five non-pineal TRbs were detected on the baseline MRI. Screening for pineal TRb had a sensitivity of 25% and specificity of 100%, for non-pineal TRb the sensitivity was 80%. It required 494 follow-up scans to detect one pineal TRb. However, when restricting the follow-up to solely suspicious glands, only 22 scans were required to detect one pineal TRb. During extended follow-up after baseline MRI, only one pineal trilateral retinoblastoma was detected in our study. Follow-up after three months should be restricted to patients with a suspicious pineal gland defined as irregularly thickening of the cyst wall (>2mm), fine nodular aspect of the cyst wall or when a solid or cystic gland exceeds the upper 99% prediction interval for size; patients with an unsuspicious cystic gland should not be followed up. Baseline MRI screening was able to detect most non-pineal trilateral retinoblastomas.

Identifiants

pubmed: 38992673
pii: S0002-9394(24)00303-9
doi: 10.1016/j.ajo.2024.07.005
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest No conflicting relationship exists for any author.

Auteurs

Christiaan M de Bloeme (CM)

European Retinoblastoma Imaging Collaboration (ERIC); Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. Electronic address: c.debloeme@amsterdamumc.nl.

Robin W Jansen (RW)

European Retinoblastoma Imaging Collaboration (ERIC); Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Joeka de Haan (J)

Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Debbie Pieperjohanns (D)

Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.

Tommaso Casseri (T)

Department of Neuroimaging and Neurointervention, Siena University Hospital, Siena, Italy.

Federica Gironi (F)

Department of Pediatrics and Neonatology, Siena University Hospital, Siena, Italy.

Alessandra Pasca (A)

Department of Pediatrics and Neonatology, Siena University Hospital, Siena, Italy.

Petra Ketteler (P)

Department of Pediatric Oncology, University Hospital Essen, Essen, Germany.

Annette C Moll (AC)

Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands; Department of Ophthalmology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Meriam Koob (M)

European Retinoblastoma Imaging Collaboration (ERIC); Department of Radiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland.

Selma Sirin (S)

European Retinoblastoma Imaging Collaboration (ERIC); Department of Diagnostic Imaging, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.

Philippe Maeder (P)

European Retinoblastoma Imaging Collaboration (ERIC); Department of Radiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland.

Paolo Galluzzi (P)

European Retinoblastoma Imaging Collaboration (ERIC); Department of Neuroimaging and Neurointervention, Siena University Hospital, Siena, Italy.

Sophia Göricke (S)

European Retinoblastoma Imaging Collaboration (ERIC); Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.

Pim de Graaf (P)

European Retinoblastoma Imaging Collaboration (ERIC); Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Marcus C de Jong (MC)

European Retinoblastoma Imaging Collaboration (ERIC); Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Classifications MeSH